Gerald J. Gleich
( out of 24 reviews )

Gerald J. Gleich, MD

Languages spoken: English

Clinical Locations

Midvalley Health Center Dermatology

Dermatology
Murray
801-581-2955

  • Gerald Gleich, MD is an allergist and immunologist with a practice focused on the treatment of eosinophil-associated diseases. These include asthma, esophagitis and hypereosinophilic syndromes, as well as more common allergic diseases such as allergic conjunctivitis, allergic rhinitis (hay fever), chronic rhinosinusitis, atopic dermatitis (eczema), and urticaria (hives). He is board certified in Internal Medicine, and Allergy and Immunology. His research interests are in the study of eosinophils and allergic inflammatory reactions.

    Specialties

    Board Certification

    American Board of Allergy & Immunology
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Allergy & Immun)

    Patient Rating

    4.9 /5
    ( out of 24 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    November 12, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Gleich is the doctor of doctors. He is relentless in his effort to identify and solve health problems. I've never had a doctor who works as hard to help solve my health needs as Dr. Gleich.

    April 09, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Extremely good care

    November 04, 2023
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Gleich was very helpful in getting me the echocardiogram that I needed at the facility closest to me, in American Fork, instead of traveling all the way up to Salt Lake City. He is easy to work with and makes me feel comfortable at each visit. He is very kind.

    August 16, 2023
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Gleich is a treasure. How lucky are we to have a world renowned immunologist here in Utah.

    July 19, 2023
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr Gleich was very informative. He was willing to assist in the care my son needed and we learned a great deal. Thank you!

    May 23, 2023
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Gleich is a very caring and knowledgeable doctor.

  • Gerald Gleich, MD is an allergist and immunologist with a practice focused on the treatment of eosinophil-associated diseases. These include asthma, esophagitis and hypereosinophilic syndromes, as well as more common allergic diseases such as allergic conjunctivitis, allergic rhinitis (hay fever), chronic rhinosinusitis, atopic dermatitis (eczema), and urticaria (hives). He is board certified in Internal Medicine, and Allergy and Immunology. His research interests are in the study of eosinophils and allergic inflammatory reactions.

    Board Certification and Academic Information

    Academic Departments Dermatology -Research Professor
    Academic Divisions Allergy / Immunology
    Board Certification
    American Board of Allergy & Immunology
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Allergy & Immun)

    Education history

    Fellowship Allergy & Immunology - Strong Memorial Hospital Fellow
    Residency Internal Medicine - Jackson Memorial Hospital Resident
    Internship Medicine - Philadelphia General Hospital Intern
    Professional Medical Medicine - University of Michigan M.D.
    Undergraduate Premedical Sciences - University of Michigan B.A.

    Selected Publications

    Journal Article

    1. Gleich GJ, Hendershot R (2023). Episodic angioedema associated with eosinophilia: Benralizumab-induced complete remission. J Allergy Clin Immunol Pract, 12(1), 259-261. (Read full article)
    2. Smith KA, Gill AS, Pollard CE, Sumsion JS, Saffari H, Ashby S, Witt BL, Shipman PA, Gabrielsen DA, Yim MT, Levy JM, Oakley GM, Orlandi RR, Gleich GJ, Alt JA, Pulsipher A (2023). An eosinophil peroxidase activity assay accurately predicts eosinophilic chronic rhinosinusitis. J Allergy Clin Immunol, 152(2), 400-407. (Read full article)
    3. Pyne AL, Hazel MW, Uchida AM, Qeadan F, Jordan KC, Holman A, Harward B, Gleich GJ, Peterson KA (2022). Oesophageal secretions reveal local food-specific antibody responses in eosinophilic oesophagitis. Aliment Pharmacol Ther, 56(9), 1328-1336. (Read full article)
    4. Rothenberg ME, Roufosse F, Faguer S, Gleich GJ, Steinfeld J, Yancey SW, Mavropoulou E, Kwon N, HES Mepolizumab Study Group (2022). Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5. J Allergy Clin Immunol Pract, 10(9), 2367-2374.e3. (Read full article)
    5. Gleich GJ, Roufosse F, Chupp G, Faguer S, Walz B, Reiter A, Yancey SW, Bentley JH, Steinfeld J, HES Mepolizumab Study Group (2021). Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study. J Allergy Clin Immunol Pract, 9(12), 4431-4440.e1. (Read full article)
    6. Squillace DL, Checkel JL, Tefferi A, Kita H, Gleich GJ (2021). Development and application of novel immunoassays for eosinophil granule major basic proteins to evaluate eosinophilia and myeloproliferative disorders. J Immunol Methods, 493, 113015. (Read full article)
    7. Muraki M, Kita H, Gleich GJ (2020). Dexamethasone and lidocaine suppress eosinophilopoiesis from umbilical cord blood cells. Clin Mol Allergy, 18(1), 24. (Read full article)
    8. Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, Gilson MJ, Bentley JH, Bradford ES, Yancey SW, Steinfeld J, Gleich GJ, HES Mepolizumab study group (2020). Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol, 146(6), 1397-1405. (Read full article)
    9. Peterson K, Lin E, Saffari H, Qeadan F, Pyne A, Firszt R, Robson J, Gleich G (2020). Food-specific antibodies in oesophageal secretions: association with trigger foods in eosinophilic oesophagitis. Aliment Pharmacol Ther, 52(6), 997-1007. (Read full article)
    10. Dong ZM, Lin E, Wechsler ME, Weller PF, Klion AD, Bochner BS, Delker DA, Hazel MW, Fairfax K, Khoury P, Akuthota P, Merkel PA, Dyer AM, Langford C, Specks U, Gleich GJ, Chinchilli VM, Raby B, Yandell M, Clayton F (2020). Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features. Am J Pathol, 190(7), 1438-1448. (Read full article)
    11. Saffari H, Peterson KA, Leiferman KM, Stabin MG, Krstyen JJ, Clayton FC, Pease LF 3rd, Yap JT, Hoffman JM, Gleich GJ (2019). Oral Administration of 99mTechnetium-Labeled Heparin in Eosinophilic Esophagitis. Mayo Clin Proc, 95(3), 449-458. (Read full article)
    12. Peterson KA, Gleich GJ, Limaye NS, Crispin H, Robson J, Fang J, Saffari H, Clayton F, Leiferman KM (2019). Eosinophil granule major basic protein 1 deposition in eosinophilic esophagitis correlates with symptoms independent of eosinophil counts. Dis Esophagus, 32(11). (Read full article)
    13. Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, OHare T, Prchal JT, Deininger MW (2019). JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 134(26), 2388-2398. (Read full article)
    14. Lee LY, Gu Q, Lin AH, Khosravi M, Gleich G (2019). Airway hypersensitivity induced by eosinophil granule-derived cationic proteins. Pulm Pharmacol Ther, 57, 101804. (Read full article)
    15. Lin AH, Athukorala A, Gleich GJ, Lee LY (2019). Cough responses to inhaled irritants are enhanced by eosinophil major basic protein in awake mice. Am J Physiol Regul Integr Comp Physiol, 317(1), R93-R97. (Read full article)
    16. Steinfeld J, Bradford ES, Brown J, Mallett S, Yancey SW, Akuthota P, Cid MC, Gleich GJ, Jayne D, Khoury P, Langford CA, Merkel PA, Moosig F, Specks U, Weller PF, Wechsler ME (2018). Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol, 143(6), 2170-2177. (Read full article)
    17. Saffari H, Peterson KA, Fang JC, Teman C, Gleich GJ, Pease LF 3rd (2012). Patchy eosinophil distributions in an esophagectomy specimen from a patient with eosinophilic esophagitis: Implications for endoscopic biopsy. J Allergy Clin Immunol, 130(3), 798-800. (Read full article)
    18. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Haferlach T, Simon HU, Reiter A, Gleich GJ (2012). Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol, 130(3), 607-612.e9. (Read full article)
    19. Plager DA, Davis MD, Andrews AG, Coenen MJ, George TJ, Gleich GJ, Leiferman KM (2009). Eosinophil ribonucleases and their cutaneous lesion-forming activity. J Immunol, 183(6), 4013-20. (Read full article)
    20. Gleich GJ, Leiferman KM (2009). The hypereosinophilic syndromes: current concepts and treatments. Br J Haematol, 145(3), 271-85. (Read full article)
    21. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ (2008). Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med, 358(12), 1215-28. (Read full article)
    22. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH (2002). Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet, 359(9317), 1577-8. (Read full article)
    23. Gleich GJ (2000). Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol, 105(4), 651-63. (Read full article)
    24. Gleich GJ, Schroeter AL, Marcoux JP, Sachs MI, OConnell EJ, Kohler PF (1984). Episodic angioedema associated with eosinophilia. N Engl J Med, 310(25), 1621-6. (Read full article)

    Review

    1. Leiferman KM, Gleich GJ (2023). The true extent of eosinophil involvement in disease is unrecognized: the secret life of dead eosinophils. [Review]. J Leukoc Biol, 116(2), 271-287. (Read full article)
    2. Chehade M, Wright BL, Atkins D, Aceves SS, Ackerman SJ, Assaad AH, Bauer M, Collins MH, Commins SP, Davis CM, Dellon ES, Doerfler B, Gleich GJ, Gupta SK, Hill DA, Jensen ET, Katzka D, Kliewer K, Kodroff E, Kottyan LC, Kyle S, Muir AB, Pesek RD, Peterson K, Shreffler WG, Spergel JM, Strobel MJ, Wechsler J, Zimmermann N, Furuta GT, Rothenberg ME (2023). Breakthroughs in understanding and treating eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERs Symposium at the 2022 American Academy of Allergy, Asthma & Immunology Meeting. [Review]. J Allergy Clin Immunol, 152(6), 1382-1393. (Read full article)
    3. Valent P, Klion AD, Roufosse F, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, Gleich GJ (2022). Proposed Refined Diagnostic Criteria and Classification of Eosinophil Disorders and Related Syndromes. [Review]. Allergy, 78(1), 47-59. (Read full article)
    4. Gleich GJ (1990). The eosinophil and bronchial asthma: current understanding. [Review]. J Allergy Clin Immunol, 85(2), 422-36. (Read full article)
    5. Frigas E, Gleich GJ (1986). The eosinophil and the pathophysiology of asthma. [Review]. J Allergy Clin Immunol, 77(4), 527-37. (Read full article)

    Editorial

    1. Gleich GJ, Leiferman KM (2022). Does Eosinophil Depletion in Gastroenteric Diseases Associated With the Hypereosinophilic Syndrome Teach Us Whether Normal Humans Need Eosinophils in 2022? J Allergy Clin Immunol Pract, 10(6), 1606-1607. (Read full article)

    Letter

    1. Gleich GJ, Leiferman KM (2021). Are Eosinophils Needed for Normal Health? [Letter to the editor]. Mayo Clin Proc, 97(4), 805. (Read full article)
    2. Zussman J, Gleich GJ (2018). Allergic rhinitis and asthma induced by boxelder bug sensitization. [Letter to the editor]. J Allergy Clin Immunol Pract, 7(4), 1365-1366. (Read full article)
    3. Ortega HG, Meyer E, Brusselle G, Asano K, Prazma CM, Albers FC, Mallett SA, Yancey SW, Gleich GJ (2019). Update on immunogenicity in severe asthma: Experience with mepolizumab. [Letter to the editor]. J Allergy Clin Immunol Pract, 7(7), 2469-2475.e1. (Read full article)
    4. Rosenberg HF, Fryer AD, Munitz A, Bochner BS, Jacoby DB, Levi-Schaffer F, Gleich GJ, Furuta GT, Rothenberg ME, Lacy P, Fulkerson PC, Hogan SP, Ackerman SJ, Foster PS (2017). In Memory and Celebration: Dr. James J. Lee. [Letter to the editor]. Clin Exp Allergy, 47(7), 980-981. (Read full article)
    5. Ortega H, Gleich G, Mayer B, Yancey S (2015). Reproducibility of a Single Blood Eosinophil Measurement as a Biomarker in Severe Eosinophilic Asthma. [Letter to the editor]. Ann Am Thorac Soc, 12(12), 1896-7. (Read full article)

    Patent

    1. Gleich GJ, Bankers-Fulbright JL, O'Grady S (2002). Topical Anesthetics for Treating Cancer. U.S. Patent No. 6391888. Washington, D.C.:U.S. Patent and Trademark Office.
    2. Gleich GJ, Ohnishi T, Hunt LW (2000). Use of Topical Anesthetics for the Manufacture of a Medicament for the Treatment of Bronchial Asthma. U.S. Patent No. 0682514. Washington, D.C.:U.S. Patent and Trademark Office.
    3. Gleich GJ, Hunt LW (2000). Methods of Treating Neutrophil-Related Diseases with Topical Anesthetics. U.S. Patent No. 60214031. Washington, D.C.:U.S. Patent and Trademark Office.
    4. Gleich GJ, Bankers-Fulbright JL (2000). Use of Agents to Treat Eosinophil-Associated Pathologies. U.S. Patent No. 6071910. Washington, D.C.:U.S. Patent and Trademark Office.
    5. Gleich GJ, Levy AM, Sandborn WJ, Tremaine WJ, Steiner BL, Phillips SF (1999). Eosinophil Granule Proteins as Indicators of Inflammatory Bowel Disorders. U.S. Patent No. 5928883. Washington, D.C.:U.S. Patent and Trademark Office.
    6. Gleich GJ (1998). Treatment of Eosinophil-Associated Pathologies by Administration of Topical Anesthetics and Glucocorticoids. U.S. Patent No. 5837713. Washington, D.C.:U.S. Patent and Trademark Office.
    7. Scott RW (1998). Basophil Granules Proteins. U.S. Patent No. 8977812. Washington, D.C.:U.S. Patent and Trademark Office.
    8. Scott RW, Gleich GJ, Wilde CG (1998). Basophil Granule Proteins. U.S. Patent No. 5747283. Washington, D.C.:U.S. Patent and Trademark Office.
    9. Gleich GJ (1997). Method for the Treatment of Bronchial Asthma by Parenteral Administration of Anionic Polymers. U.S. Patent No. 5681555. Washington, D.C.:U.S. Patent and Trademark Office.
    10. Gleich GJ, Ohnishi T, Hunt LW (1997). Method for the Treatment of Eosinophil-Associated Diseases by Administration of Topical Anesthetics. U.S. Patent No. 5631267. Washington, D.C.:U.S. Patent and Trademark Office.
    11. Gleich GJ, Ohnishi T, Hunt LW (1996). Method for the Treatment of Bronchial Asthma by Administration of Topical Anesthetics. U.S. Patent No. 5510339. Washington, D.C.:U.S. Patent and Trademark Office.
    12. Gleich GJ (1996). Method for the Treatment of Eosinophil-Associated Conditions with Anionic Polymers. U.S. Patent No. 5498410. Washington, D.C.:U.S. Patent and Trademark Office.
    13. Scott RW, Gleich GJ, Wilde CG (1995). Basophil Granule Proteins. U.S. Patent No. 5476839. Washington, D.C.:U.S. Patent and Trademark Office.
    14. Scott RW, Gleich GJ, Wilde CG (1995). Basophil Granule Proteins. U.S. Patent No. 5470825. Washington, D.C.:U.S. Patent and Trademark Office.
    15. Gleich GJ (1993). Method for the Treatment of Hypersensitivity Diseases by Administration of Anionic Polymers. U.S. Patent No. 5250293. Washington, D.C.:U.S. Patent and Trademark Office.
    16. Gleich GJ, Wasmoen TL (1987). Method for the Determination of the Imminence of Labor. U.S. Patent No. 4710475. Washington, D.C.:U.S. Patent and Trademark Office.

  • News & Podcasts

    News